NOTUM is a potential pharmacodynamic biomarker of Wnt pathway inhibition

Babita Madan; Zhiyuan Ke; Zheng Deng Lei; Frois Ashley Oliver; Masanobu Oshima; May Ann Lee; Steve Rozen; David M. Virshup

doi:10.18632/oncotarget.7157

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

NOTUM is a potential pharmacodynamic biomarker of Wnt pathway inhibition

Babita Madan _, Zhiyuan Ke, Zheng Deng Lei, Frois Ashley Oliver, Masanobu Oshima, May Ann Lee, Steve Rozen and David M. Virshup

PDF | HTML | How to cite

Oncotarget. 2016; 7:12386-12392. https://doi.org/10.18632/oncotarget.7157

Metrics: PDF 2478 views | HTML 3002 views | ?

Abstract

Babita Madan1, Zhiyuan Ke2, Zheng Deng Lei1, Frois Ashley Oliver1, Masanobu Oshima3, May Ann Lee2, Steve Rozen1, David M. Virshup1,4

1Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore

2Experimental Therapeutics Centre, A*STAR, Biopolis, Singapore

3Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan

4Department of Pediatrics, Duke University, Durham, NC, USA

Correspondence to:

David M. Virshup, e-mail: [email protected]

Babita Madan, e-mail: [email protected]

Keywords: Wnt signaling, Notum, Biomarker, PORCN inhibitor

Received: September 06, 2015 Accepted: January 23, 2016 Published: February 03, 2016

ABSTRACT

Activation of Wnt signaling due to Wnt overexpression or mutations of Wnt pathway components is associated with various cancers. Blocking Wnt secretion by inhibiting PORCN enzymatic activity has shown efficacy in a subset of cancers with elevated Wnt signaling. Predicting response to upstream Wnt inhibitors and monitoring response to therapeutics is challenging due to the paucity of well-defined biomarkers. In this study we identify Notum as a potential biomarker for Wnt driven cancers and show that coordinate regulation of NOTUM and AXIN2 expression may be a useful predictor of response to PORCN inhibitors. Most importantly, as NOTUM is a secreted protein and its levels in blood correlate with tumor growth, it has potential as a pharmacodynamic biomarker for PORCN and other Wnt pathway inhibitors.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7157

Publication Alerts

Research Papers:

NOTUM is a potential pharmacodynamic biomarker of Wnt pathway inhibition

Abstract